1. Home
  2. TRX vs TLSA Comparison

TRX vs TLSA Comparison

Compare TRX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$1.35

Market Cap

383.1M

Sector

N/A

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.03

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
TLSA
Founded
1990
2013
Country
Canada
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.1M
145.1M
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
TRX
TLSA
Price
$1.35
$1.03
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$1.70
N/A
AVG Volume (30 Days)
3.1M
503.6K
Earning Date
04-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.76
52 Week High
$2.80
$2.35

Technical Indicators

Market Signals
Indicator
TRX
TLSA
Relative Strength Index (RSI) 64.96 43.30
Support Level $1.07 $0.76
Resistance Level $2.00 $1.20
Average True Range (ATR) 0.08 0.07
MACD 0.02 -0.00
Stochastic Oscillator 81.59 43.02

Price Performance

Historical Comparison
TRX
TLSA

About TRX TRX Gold Corporation

TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: